

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/239290 A1

(51) International Patent Classification:

C07K 14/725 (2006.01) A61P 31/20 (2006.01)
A61K 35/17 (2015.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/SG2022/050892

(22) International Filing Date:

08 December 2022 (08.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202210626787.7 05 June 2022 (05.06.2022) CN

(71) Applicant: SCG CELL THERAPY PTE. LTD. [SG/SG];
50 Raffles Place, #37-00, Singapore Land Tower, Singapore
048623 (SG).

(72) Inventors: PROTZER, Ulrike; Anzlgutstr. 45, 81735 Munich (DE). WISSKIRCHEN, Karin; Rosenheimer Str. 40, 81669 Munich (DE). HUANG, Yanzhou; 4F, Building 2, NO. 111 Xiangke Road, Pudong District, Shanghai, Shanghai, Shanghai (CN). JIN, Tao; 4F, Building 2, NO. 111 Xiangke Road, Pudong District, Shanghai, Shanghai, Shanghai (CN). ZHANG, Ke; 4F, Building 2, NO. 111 Xiangke Road, Pudong District, Shanghai, Shanghai, Shanghai (CN).

(74) Agent: VIERING, JENTSCHURA & PARTNER LLP;
P.O. Box 1088, Rochor Post Office, Rochor Road, Singapore 911833 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HBV SURFACE ANTIGEN SPECIFIC T CELL RECEPTORS AND USES THEREOF




Figure 10

(57) Abstract: Provided are HLA-A02 restricted T cell receptors (TCRs) that specifically target HBV surface antigen which is a S20 peptide consisting of FLLTRILTI and the T cells expressing said TCRs. It also relates to the nucleic acid molecules and vectors encoding said TCRs and their medical uses in reducing HBV antigen-positive tumour cells and treating or preventing HBV infections and related diseases.